Thread by @DocCatenacci

It will be important to look at the data closely, particularly by histology. Merck’s KEYTRUDA® (pembrolizumab) in Combination W Chemo Significantly Improved OS and PFS Compared W Chemo in 1L Metastatic Esophageal Cancer | Business Wire businesswire.com/news/home/2020…

We must recall that a ~500 pt study of the exact same regimen KN062 was recently statistically negative (HR0.85 p=0.046) in CPS>0 in adeno. Now the same regimen in KN590 N=749, in all-comers irrespective of PDL1 but including SCC, is +ve. What could be driving this difference?🤔

Let’s see the data: the make-up by histology (& PDL1!) & the benefit magnitude diffs (as might be expected) b/w them before we jump to conclusions on both CM577 and KN590, and also CM649. Let’s not make press releases drive the science! #esmo2020 is going to be a doozy for #GEA!!

Also I am looking forward to the detailed discussion putting these new studies into perspective by @LizzySmyth1 & others!!!!! #esmo2020 @KlempnerSam @JoeChaoMD @ILSONDavid @DrGarridoOncoGI @myESMO @marshalj23 @AudreyKamMD @AnwaarSaeed3 @SteveMaronMD @GIcancerDoc @paphilip

@aakonc @agrothey @mgfakih @HH_Oncodr @pashtoonkasi @YJanjigianMD @antonyruggeri @rutikamehtaMD @RussellPetty19 @BiachiTiago @UmutDisel @ECActionNetwork @OncoAlert @eirinipec @DrCrystalD @Thalcin @RenoHemonc @KoheiShitara @OncLive @DrGarridoOncoGI @FDAOncology @DrBonillaOnc

@DrR_DUNNE @rcarvalhoonco @NataliyaUboha @mgibson21212 @Marindoc @BenWestphalen @benweinbergmd @weoncologists @mdmanishshah @LFerri123 I just realized going through contacts how many are so devoted to improving outcomes of #GEA!